UPDATE: Wedbush Raises PT on Intercept Pharmaceuticals on Decreased Regulatory Risk

In a report published Monday, Wedbush analyst Liana Moussatos reiterated an Outperform rating on Intercept Pharmaceuticals (NASDAQ: ICPT ), and raised the price target from $46.00 to $56.00. In the report, Moussatos noted, “We have become more comfortable with FDA risk due to the EASL Supergroup abstract supporting the UK